Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Faron Pharmaceuticals Oy ( (GB:FARN) ) is now available.
Faron Pharmaceuticals Ltd has announced its financial reporting schedule for 2025, with its full-year financial statement and annual report for 2024 to be released on February 27, 2025, and the half-year financial report for the first half of 2025 due on August 27, 2025. The company also plans to hold its Annual General Meeting on March 21, 2025. This announcement is a routine update that provides stakeholders with important dates for financial disclosures and corporate governance meetings, reflecting the company’s ongoing commitment to transparency and shareholder engagement.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies to combat cancer. Its primary focus is on utilizing the promise of immunotherapy to treat a wider patient population by innovating ways to control and utilize the immune system. The company’s lead asset, bexmarilimab, is an anti-Clever-1 humanized antibody, currently in Phase I/II clinical trials, aimed at treating hematological cancers by reprogramming myeloid cell function.
YTD Price Performance: -32.62%
Average Trading Volume: 18,169
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £177.3M
For detailed information about FARN stock, go to TipRanks’ Stock Analysis page.
